Research on Evaluation of Dongguan Pharmaceutical Innovation Ability under the Background of Industrial Transformation and Upgrading Strategy

Abstract

In the context of the "Healthy China" initiative and the strategy of industrial transformation and upgrading, pharmaceutical innovation capability has emerged as an indispensable and crucial element for the development of the "Healthy China" strategy. This paper first comprehensively reviews theoretical perspectives on domestic and international pharmaceutical innovation capability research. Subsequently, it deeply analyzes the multiple factors influencing the pharmaceutical innovation capability in Dongguan. The study adopts the expert consultation method to establish evaluation criteria, utilizes the Analytic Hierarchy Process (AHP) to determine indicator weights and validate their rationality, and ultimately applies a fuzzy comprehensive evaluation model to process and analyze the data. The research results indicate that the constructed pharmaceutical innovation capability evaluation system exhibits significant advantages in terms of scientificity and practicality. The analysis of the comprehensive evaluation values reveals a positive development trend in Dongguan's pharmaceutical innovation capability, with the composite index continuously rising. However, it is still necessary to strengthen relevant policy support in order to promote the sustainable development of pharmaceutical innovation in Dongguan.